SBIR/STTR Research Award
Novel small-molecule targeted therapy for prostate cancer
Award amount
$224,999Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MetCure Therapeutics LLC
- Proposal award date
- 2016-09-15
- Contract end date
- 2018-08-31
- UEI
- CGKMNL6SUY65
- Solicitation number
- PA15-270
- Topic code
- 102
Research abstract
Enzalutamide resistance is a major obstacle in the treatment of metastatic castration resistant prostate cancer
mCRPC Recently we developed a small molecule lead compound BKM and demonstrated its potent
activity against bone metastatic prostate cancer cells In this Phase I STTR application we hypothesize that
BKM is a novel targeted therapy to overcome enzalutamide resistance and effectively target bone
metastasis Two Aims are proposed Aim will evaluate the in vivo pharmacokinetics distribution and efficacy
of BKM in targeting enzalutamide resistant bone metastatic prostate cancer in animal models Aim will
determine the mechanism of action of BKM in mCRPC cells The project has immediate therapeutic
potential in treating a lethal disease In this Phase I STTR application we will develop a small molecule drug BKM to overcome enzalutamide
resistance and treat bone metastatic prostate cancer a major cause of cancer death in American men This project
has immediate potential in treating a lethal disease reducing cancer morbidity and improving healthcare in the United
States and globally
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Small-molecule therapy for metastatic castration-resistant prostate cancer
- Small molecule therapy for metastatic prostate cancer
- A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
4 SBIR/STTR records share this UEI (2015–2021). Reported award amounts total $2,546,169. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services